SCHEMBL23684304

SCHEMBL23684304

O=C(O)c1cccc(C=C2CCOCC2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UNG P13051 1/20 0.53
▸ SRD5A1 P18405 1/20 0.51
▸ KMO O15229 2/20 0.48
▸ TTR P02766 4/20 0.46
▸ FBP1 P09467 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ P4HB P07237 2/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA6 P23280 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28161452 0.84 SRD5A1 (0.60) UNGSRD5A1KMOTTRFBP1
SCHEMBL17982828 0.81 SRD5A1 (0.46) UNGSRD5A1KMOTTRFBP1
SCHEMBL23684239 0.79 SLC7A5 (0.41) SRD5A1TDP1LMNAP4HB
SCHEMBL2277720 0.77 ALDH1A1 (0.41) UNGTDP1MAPTCA12CA1
SCHEMBL14931462 0.76 UNG (0.50) UNGSRD5A1KMOTTRFBP1
SCHEMBL5732625 0.76 LMNA (0.38) SRD5A1TDP1LMNACYP2C9
SCHEMBL16053002 0.75 ALDH1A1 (0.47) TDP1LMNAMAPTRAB9ASMN1; SMN2
Isophthalic Acid SCHEMBL6410358 0.74 KMO (0.61) UNGKMOTDP1LMNAMAPT
Isophthalic Acid SCHEMBL9136669 0.73 KMO (0.59) UNGKMOTDP1LMNAMAPT
SCHEMBL8899992 0.72 TTR (0.79) UNGSRD5A1KMOTTRFBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN UNG 3774/4885SRD5A1 320/4885KMO 2774/4885
US-11077101-B1 Compounds and methods of use XDH, F12, LPXN UNG 3774/4885SRD5A1 320/4885KMO 2774/4885
US-20230060499-A1 COMPOUNDS AND METHODS OF USE XDH, F12, LPXN UNG 3774/4885SRD5A1 320/4885KMO 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback